Marketing Of Testosterone Replacement Therapy Comes Under Suspicion
Free Image Courtesy of FreeDigitalPhoto.net
Is it normal aging or low testosterone?
This is the question being asked by government researchers, specifically, the National Institute on Aging, which has seen big advertising dollars spent pharmaceutical companies hoping to turn old age into a treatable disease.
There is no real agreement on what the effects of low testosterone as one ages has on the body.
The normal range of 300 and 1,000 nanograms per deciliter fluctuates during the day and what seems low for one individual produces no adverse affects in another.
Unknown side affects, and dubious claims made by research funded by drug makers calls into question the validity of treatment claims.
Baby boomers are also pushing an industry to supply the “fountain of youth” when real vitality is better obtained through lifestyle choices than through medicine.
Adding to the confusion over what defines “low testosterone,” there’s not much understanding of whether testosterone replacement therapy actually improves men’s symptoms. Evidence of the benefits of testosterone is mixed, and the potential health risks are serious. The largest study conducted to date, a 2008 trial involving 230 patients in the Netherlands, found no improvement in muscle strength, cognitive thinking, bone density or overall quality of life among men taking testosterone. Muscle mass increased 1.2 percent, but not enough to improve physical mobility.
The National Institute on Aging is currently conducting an 800-man trial to definitively answer whether testosterone therapy improves walking ability, sexual function, energy, memory and blood cell count in men 65 years and older. But those results aren’t expected until 2014.
In addition to concerns about testosterone’s effectiveness, the long-term side effects of the hormone are not entirely understood because most trials to date have only followed patients for a few months. But the most serious risks include heart problems and prostate cancer. In fact, all testosterone drugs carry a warning that the hormone should not be given to men who have a personal or family history of prostate cancer.